ECSP055626A - NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE - Google Patents
NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USEInfo
- Publication number
- ECSP055626A ECSP055626A EC2005005626A ECSP055626A ECSP055626A EC SP055626 A ECSP055626 A EC SP055626A EC 2005005626 A EC2005005626 A EC 2005005626A EC SP055626 A ECSP055626 A EC SP055626A EC SP055626 A ECSP055626 A EC SP055626A
- Authority
- EC
- Ecuador
- Prior art keywords
- effectors
- pharmaceutical use
- procedures
- preparation
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Se describen conjugados de epotilonas y derivados de epotilonas como efectores con biomoléculas adecuadas (como unidades de reconocimiento. Su producción se lleva a cabo haciendo reaccionar los efectores con ligadores adecuados y los compuestos que son producidos se conjugan con las unidades de reconocimiento. Se describe el uso farmacéutico de los conjugados para el tratamiento de procesos neurodegenerativos o asociados con la angiogénesis.Conjugates of epothilones and derivatives of epothilones are described as effectors with suitable biomolecules (as recognition units. Their production is carried out by reacting the effectors with suitable linkers and the compounds that are produced are conjugated with the recognition units. Pharmaceutical use of conjugates for the treatment of neurodegenerative processes or associated with angiogenesis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10234975A DE10234975A1 (en) | 2002-07-31 | 2002-07-31 | New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis |
DE10305098A DE10305098A1 (en) | 2003-02-07 | 2003-02-07 | New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis |
US45167303P | 2003-03-05 | 2003-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055626A true ECSP055626A (en) | 2005-04-18 |
Family
ID=31498923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005626A ECSP055626A (en) | 2002-07-31 | 2005-02-24 | NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1524979A2 (en) |
JP (1) | JP2006505627A (en) |
KR (1) | KR20050026033A (en) |
AU (1) | AU2003253365A1 (en) |
BR (1) | BR0313043A (en) |
CA (1) | CA2492437A1 (en) |
CO (1) | CO5700741A2 (en) |
EC (1) | ECSP055626A (en) |
HR (1) | HRP20050186A2 (en) |
IL (1) | IL166039A0 (en) |
IS (1) | IS7708A (en) |
MX (1) | MXPA05001282A (en) |
NO (1) | NO20051038L (en) |
NZ (1) | NZ537870A (en) |
PL (1) | PL374528A1 (en) |
WO (1) | WO2004012735A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK11452001A3 (en) * | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
JP4791183B2 (en) | 2002-08-23 | 2011-10-12 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | Synthesis and use of epothilone, its intermediates and analogues |
GB0221312D0 (en) | 2002-09-13 | 2002-10-23 | Novartis Ag | Organic compounds |
EP1581218A1 (en) * | 2002-12-05 | 2005-10-05 | Schering AG | Epothilone analogs for site specific delivery in the treatment of proliferative diseases |
DE10256982A1 (en) | 2002-12-05 | 2004-06-24 | Schering Ag | New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases |
WO2005074901A2 (en) * | 2004-01-30 | 2005-08-18 | Schering Ag | New effector conjugates, process for their production and their pharmaceutical use |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
JP5149620B2 (en) | 2004-07-23 | 2013-02-20 | エンドサイト,インコーポレイテッド | Bivalent linker and conjugate thereof |
AR061181A1 (en) | 2006-05-25 | 2008-08-13 | Bristol Myers Squibb Co | AZIRIDINIL-EPOTILONE COMPOUNDS |
PE20080102A1 (en) * | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
WO2008147941A1 (en) | 2007-05-25 | 2008-12-04 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
IT1401451B1 (en) * | 2010-06-10 | 2013-07-26 | Chemi Spa | NEW PROCESS OF PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-IL-METHANOL E (R) -2- [3- (DIISOPROPYLAMINOUS) -1-PHENYLPROPYL] -4- ( hydroxymethyl) Phenol. |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
IN2015DN04147A (en) | 2012-10-16 | 2015-10-16 | Endocyte Inc | |
KR102338660B1 (en) * | 2016-10-17 | 2021-12-10 | 화이자 인코포레이티드 | Anti-EDB Antibodies and Antibody-Drug Conjugates |
KR102377416B1 (en) * | 2017-06-30 | 2022-03-21 | 엘지디스플레이 주식회사 | Display Device |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK130984A (en) * | 1983-03-07 | 1984-09-08 | Smithkline Beckman Corp | Leukotriene antagonists |
IL107400A0 (en) * | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
US5942555A (en) * | 1996-03-21 | 1999-08-24 | Surmodics, Inc. | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001064650A2 (en) * | 2000-03-01 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research Center | Synthesis of epothilones, intermediates thereto and analogues thereof |
CA2404938C (en) * | 2000-04-28 | 2011-11-01 | Kosan Biosciences, Inc. | Production of polyketides |
US6441213B1 (en) * | 2000-05-18 | 2002-08-27 | National Starch And Chemical Investment Holding Corporation | Adhesion promoters containing silane, carbamate or urea, and donor or acceptor functionality |
US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
DE10041221A1 (en) * | 2000-08-22 | 2002-03-14 | Deutsches Krebsforsch | Process for the preparation of water-soluble saccharide conjugates and saccharide mimetics by the Diels-Alder reaction and their use as therapeutics or diagnostics |
GB0116143D0 (en) * | 2001-07-02 | 2001-08-22 | Amersham Pharm Biotech Uk Ltd | Chemical capture reagent |
-
2003
- 2003-07-31 IL IL16603903A patent/IL166039A0/en unknown
- 2003-07-31 NZ NZ537870A patent/NZ537870A/en unknown
- 2003-07-31 AU AU2003253365A patent/AU2003253365A1/en not_active Abandoned
- 2003-07-31 CA CA002492437A patent/CA2492437A1/en not_active Abandoned
- 2003-07-31 JP JP2005506073A patent/JP2006505627A/en active Pending
- 2003-07-31 WO PCT/EP2003/008483 patent/WO2004012735A2/en active Application Filing
- 2003-07-31 MX MXPA05001282A patent/MXPA05001282A/en not_active Application Discontinuation
- 2003-07-31 BR BR0313043-6A patent/BR0313043A/en not_active IP Right Cessation
- 2003-07-31 EP EP03743752A patent/EP1524979A2/en not_active Withdrawn
- 2003-07-31 PL PL03374528A patent/PL374528A1/en not_active Application Discontinuation
- 2003-07-31 KR KR1020057001569A patent/KR20050026033A/en not_active Application Discontinuation
-
2005
- 2005-02-23 IS IS7708A patent/IS7708A/en unknown
- 2005-02-24 CO CO05017568A patent/CO5700741A2/en not_active Application Discontinuation
- 2005-02-24 EC EC2005005626A patent/ECSP055626A/en unknown
- 2005-02-25 NO NO20051038A patent/NO20051038L/en not_active Application Discontinuation
- 2005-02-25 HR HR20050186A patent/HRP20050186A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2492437A1 (en) | 2004-02-12 |
WO2004012735A2 (en) | 2004-02-12 |
EP1524979A2 (en) | 2005-04-27 |
KR20050026033A (en) | 2005-03-14 |
NZ537870A (en) | 2007-03-30 |
MXPA05001282A (en) | 2005-04-28 |
IL166039A0 (en) | 2006-01-15 |
BR0313043A (en) | 2005-06-14 |
CO5700741A2 (en) | 2006-11-30 |
AU2003253365A1 (en) | 2004-02-23 |
JP2006505627A (en) | 2006-02-16 |
WO2004012735A3 (en) | 2004-05-27 |
HRP20050186A2 (en) | 2005-10-31 |
PL374528A1 (en) | 2005-10-31 |
NO20051038L (en) | 2005-04-06 |
IS7708A (en) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055626A (en) | NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE | |
HN1999000124A (en) | SUBSTITUTED PYRAZOLE DERIVATIVES. | |
UY27455A1 (en) | DERIVATIVES N- (1,4,5,6-TETRAHIDRO-CICLOPENTAPIRAZOL -3-IL) - REPLACED. ITS OBTAINING AND USE AS DRUGS. | |
UY27878A1 (en) | INDOLINFENYL SULFONAMIDE DERIVATIVES | |
SV2003001107A (en) | IMIDAZOTRIAZINAS REF.LEA 35368 | |
DOP2000000109A (en) | THIAZOLILAMIDE DERIVATIVES | |
MX9304819A (en) | NEW XANTINA DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION. | |
ECSP045178A (en) | ARIL ÚREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS | |
PA8577001A1 (en) | HETEROCICLICALLY SUBSTITUTED BENZOILUREAS, PROCEDURE FOR PREPARATION AND USE AS PHARMACOS | |
SV1999000009A (en) | DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL REF. PG3388 / SV | |
CY1107207T1 (en) | NEW ACTIVE COGNITION PRODUCTS, PROCEDURE FOR THEIR PRODUCTION AND PHARMACEUTICAL USE | |
CR9182A (en) | DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT | |
BR0313198A (en) | Epothilone Derivatives | |
EA200500223A1 (en) | NEW CONJUGATES - EFFECTORS, METHOD OF THEIR PRODUCTION AND THEIR PHARMACEUTICAL APPLICATION | |
UY26133A1 (en) | SUBSTITUTED DERIVATIVE OF PYRAZOLE. | |
UY26951A1 (en) | DERIVATIVES OF OWN ACID | |
BR0312863A (en) | Polyethylene glycol aldehyde derivatives | |
UY27451A1 (en) | 2,5-DIAMIDOINDOLES REPLACED AND ITS USE | |
GT200800066A (en) | DERIVATIVES OF 9-CHLORINE-15-DEOXIPROSTAGLANDIN, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT. | |
ES2075234T3 (en) | IMINOTIAZOLINES, ITS PRODUCTION AND USE AS HERBICIDES, AND INTERMEDIATE PRODUCTS FOR ITS PRODUCTION. | |
PA8579401A1 (en) | DERIVATIVES OF 2,3-DIHIDRO-ISOINDOL-1-ONA AS MAO-B INHIBITORS | |
ECSP044966A (en) | FLIBANSERINE STABLE POLYMORPH COMPOSITE, INDUSTRIAL PROCEDURE FOR PREPARATION, AND USE OF IT TO PREPARE MEDICINES | |
ECSP044988A (en) | DERIVATIVES OF THE INDAN ACETIC ACID AND ITS USE AS PHARMACEUTICAL, INTERMEDIATE, AND PREPARATION METHODS | |
ECSP034630A (en) | PILULAR AND HYDRO-ALCOHOLIC EXTRACT OF ARISTEGUIETIA GLUTINOSA LAM (MATICO) | |
ECSP961969A (en) | NEW DERIVATIVES OF PHENYLAMIDINE PROCEDURES FOR ITS PREPARATION AND USE AS MEDICINES |